$TMDX

TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

TransMedics Group, Inc. (Nasdaq: TMDX) said it granted non-qualified stock options for 18,762 shares and 12,414 restricted stock units to nine employees on July 29, 2026 as inducement awards under Nasdaq Listing Rule 5635(c)(4). Options exercise price was $78.00, the July 29 closing price, with 10-year terms.

Original reporting
Published Aug 3, 2026, 8:05 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 3, 2026, 9:17 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) — source image
Decision brief

The 30-second read

$TMDXNeutralLow
01

Why it matters

The disclosure details inducement non-qualified stock options and restricted stock units granted to employees, approved by the Compensation Committee under Nasdaq’s inducement listing rule. It does not include financial results, forward guidance, or strategic transactions.

02

Market read

This is a corporate equity-compensation disclosure with defined terms, typically low market impact absent other catalysts.

03

What to watch

The article does not quantify total dilution impact, grant size versus shares outstanding, or any performance conditions beyond service-based vesting, limiting tradable conclusions.

Relevance 4/10Novelty 3/10Timing: today’s PR disclosure of July 29, 2026 inducement equity grants

Background

TransMedics is a medical technology company focused on portable extracorporeal warm perfusion and donor organ assessment for transplantation.

Company-level read

Ticker impact

$TMDXNeutralHigh confidence
Context

TransMedics disclosed July 29, 2026 inducement grants under Nasdaq Rule 5635(c)(4), including $78.00 option exercise price and RSU vesting terms.

Expected impact

Low near-term impact; any reaction would be sentiment-driven rather than fundamental.

Evidence & confidence

The release is a standard inducement-plan equity award disclosure with no guidance change, deal, or operational update.

Market effects

Minimal. Inducement equity grants do not change transplant-tech fundamentals or competitive positioning.

None indicated; company-specific PR only.

None indicated.

Counterpoint

Traders could treat the $78.00 strike as a signal of internal valuation support, but the article provides no comparative context or scale versus prior grants.

Key entities

  • TransMedics Group, Inc.

    Announced inducement equity grants under Nasdaq Listing Rule 5635(c)(4), including option exercise price and RSU vesting schedule.

  • Nasdaq Listing Rule 5635(c)(4)

    Rule governing inducement awards for new employees, referenced as the basis for the grants.

Related articles

$TMDXMed

Why TransMedics Stock Is Sinking Today

TransMedics (NASDAQ: TMDX) shares fell about 8% after its Q2 results. The company reported 21% sales growth, but adjusted net income dropped from $35M in Q2 last year to $16M this year, below expectations. Management said about $19M of the change reflected spending on a next-gen kidney OCS, clinical programs, and a manufacturing plant in Italy.

$TMDXHighAI 9/10

TransMedics Reports Second Quarter 2026 Financial Results

TransMedics Group (Nasdaq: TMDX) reported Q2 2026 revenue of $189.9 million, up 21% year over year, with product revenue $111.2 million and service revenue $78.8 million. Net income was $14.7 million, or $0.41 per diluted share. The company raised full-year 2026 revenue guidance (excluding PAD Aviation) to $737 million to $757 million.

$TMDXMed

TransMedics Group, Inc. (TMDX): Results of Operations and Financial Condition

TransMedics Group, Inc. (TMDX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 TransMedics Reports Second Quarter 2026 Financial Results Andover, Mass. – August 4, 2026 – TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and

$TMDXMed

Is TransMedics Group, Inc. (TMDX) Stock Still a MedTech Growth Opportunity After Analyst Target Cut?

TheFly reported July 6 that Evercore ISI cut its TransMedics Group (TMDX) price target to $90 from $100 while keeping an Outperform rating, citing generally stable procedure volumes and capital spending trends. On the same day, TMDX said it will invest in PAD Aviation to expand its Organ Care System OCS program into Europe, aiming to improve organ access and transplant logistics.

$NKELow

Nike Installs Former Foot Locker Supply Chain Chief as Converse COO

Nike has appointed Kristin Bauer, former Foot Locker supply chain chief, as Converse's new COO. Bauer starts Sept. 14. Converse reported a 32% revenue decline in Q4, raising concerns about its future. Nike's CEO stated Converse is not for sale. This follows Nike's hiring of Walmart's Jane Ewing as EVP and chief commercial officer.